1. Ipatasertib-abiraterone treatment significantly improved progression-free survival compared to placebo-abiraterone in patients with PTEN-loss metastatic castration-resistant prostate cancer. 2. Grade 3 ...
1. Ipatasertib-abiraterone treatment significantly improved progression-free survival compared to placebo-abiraterone in patients with PTEN-loss metastatic castration-resistant prostate cancer. 2. Grade ...
1. Among patients with high-risk prostate cancer receiving guideline-concordant multimodal therapy, prostate cancer-specific mortality outcomes were equivalent among radical prostatectomy, ...
1. Radiolabeled Lutetium-177 offered greater PSA response versus current standard of care, cabazitaxel. 2. Fewer grade 3-4 adverse events occurred ...
1. The use of long-term transdermal estrogen for castration therapy for prostate cancer showed no difference in cardiovascular events versus ...
![Reduced neuronal BRCA1 associated with decreased DNA repair in Alzheimer’s disease [PreClinical]](https://www.2minutemedicine.com/wp-content/uploads/2015/12/DNA_Furchen_edited-350x250.png)
1. Men with metastatic prostate cancer had a significantly higher incidence of germline mutations mediating DNA-repair processes compared to men ...
Image: PD 1. Men with localized, non-metastatic prostate cancer who underwent radical prostatectomy demonstrated lower mortality rates compared to treatment ...
